{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:12:25Z","timestamp":1785208345788,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Microsatellite instability-high (MSI-H) status in colorectal cancer is associated with a favorable prognosis, but its predictive value for adjuvant chemotherapy (ACT) benefit for patients with stage II disease remains controversial, particularly when histopathologic risk factors are taken into account. This study aimed to evaluate the impact of ACT on overall survival (OS) for patients with stage II MSI-H colon cancer stratified by pathologic risk and stage III MSI-H colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of the National Cancer Database (2013\u20132019) was performed, identifying 8025 patients with stage II or III MSI-H colon adenocarcinoma who underwent surgical resection. The stage II patients were stratified into low- and high-risk cohorts based on adverse pathologic features including pT4 stage, lymphovascular invasion, perineural invasion, positive margins, or and fewer than 12 lymph nodes examined. Inverse probability of treatment-weighting was applied to balance the covariates, and OS was estimated using weighted Kaplan\u2013Meier and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 8025 patients included in the study, 4981 had stage II disease and 3044 had stage III disease. Among the 3501 low-risk stage II patients, ACT was administered to only 5.9% and was not associated with an OS benefit (hazard ratio [HR], 0.92; 95% confidence interval [CI] 0.58\u20131.47;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.73). In contrast, among the 1480 high-risk stage II patients, 19.1% received ACT, which was associated with a 62% reduction in mortality risk (HR, 0.38; 95% CI 0.25\u20130.57;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Increasing histopathologic risk burden correlated with higher mortality. In the stage III cohort, ACT was administered to 66.5% of the 3044 patients and significantly improved OS (HR, 0.53; 95% CI 0.45\u20130.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Notably, one third of the patients with stage III disease did not receive ACT despite the guideline recommendations for ACT in this population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A patient\u2019s MSI-H status alone should not preclude the use of ACT in colon cancer. This study demonstrated a significant survival benefit of ACT for both high-risk stage II and stage III MSI-H patients. Histopathologic risk stratification should guide treatment decisions for stage II MSI-H colon cancer, and ACT may be recommended for patients with multiple adverse pathologic features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18285-7","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:22:40Z","timestamp":1759854160000},"page":"9510-9520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adjuvant Chemotherapy and Survival in MSI-High Stages II and III Colon Cancer: Impact of Histopathologic Risk Stratification"],"prefix":"10.1245","volume":"32","author":[{"given":"Metincan","family":"Erkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Benlice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Karahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Ozben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgi","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Gorgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"18285_CR1","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1158\/1055-9965.EPI-08-0512","volume":"17","author":"JN Poynter","year":"2008","unstructured":"Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008;17:3208\u201315. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0512.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"18285_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GAM, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266\u201373. https:\/\/doi.org\/10.1038\/sj.bjc.6604867.","journal-title":"Br J Cancer"},{"key":"18285_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010019","volume":"97","author":"S Kang","year":"2018","unstructured":"Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Med Baltim. 2018;97:e0019. https:\/\/doi.org\/10.1097\/MD.0000000000010019.","journal-title":"Med Baltim"},{"key":"18285_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2019.02.002","volume":"75","author":"J Taieb","year":"2019","unstructured":"Taieb J, Andr\u00e9 T, Auclin E. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treat Rev. 2019;75:1\u201311. https:\/\/doi.org\/10.1016\/j.ctrv.2019.02.002.","journal-title":"Cancer Treat Rev"},{"key":"18285_CR5","doi-asserted-by":"publisher","first-page":"e240029","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, et al. Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:e240029. https:\/\/doi.org\/10.6004\/jnccn.2024.0029.","journal-title":"J Natl Compr Canc Netw."},{"key":"18285_CR6","unstructured":"Research C for DE and FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer. FDA. Published online 4 August 2025. Retrieved 19 April 2025 at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer."},{"key":"18285_CR7","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.clcc.2020.08.001","volume":"20","author":"BL Sun","year":"2021","unstructured":"Sun BL. Current microsatellite instability testing in management of colorectal cancer. Clin Colorect Cancer. 2021;20:e12\u201320. https:\/\/doi.org\/10.1016\/j.clcc.2020.08.001.","journal-title":"Clin Colorect Cancer"},{"key":"18285_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/annonc\/mdy424.047","volume":"29","author":"M Chalabi","year":"2018","unstructured":"Chalabi M, Fanchi LF, Van Den Berg JG, et al. Neoadjuvant ipilimumab plus nivolumab in early-stage colon cancer. Ann Oncol. 2018;29:731. https:\/\/doi.org\/10.1093\/annonc\/mdy424.047.","journal-title":"Ann Oncol"},{"key":"18285_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","author":"YL Verschoor","year":"2022","unstructured":"Verschoor YL, van den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. J Clin Oncol. 2022;40(16_suppl):3511.\u00a0\u00a0https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.3511.","journal-title":"J Clin Oncol"},{"key":"18285_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41:1541\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00046.","journal-title":"J Clin Oncol"},{"key":"18285_CR11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3390\/cancers11101567","volume":"11","author":"C Evrard","year":"2019","unstructured":"Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Cancers Basel. 2019;11:1567. https:\/\/doi.org\/10.3390\/cancers11101567.","journal-title":"Cancers Basel"},{"key":"18285_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863\u201375. https:\/\/doi.org\/10.1093\/jnci\/djr153.","journal-title":"J Natl Cancer Inst"},{"key":"18285_CR13","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21:1620\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(20)30527-1.","journal-title":"Lancet Oncol"},{"key":"18285_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2020;31:1291\u2013305. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.022.","journal-title":"Ann Oncol"},{"key":"18285_CR15","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31:2963\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.49.5283.","journal-title":"J Clin Oncol"},{"key":"18285_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"key":"18285_CR17","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358. https:\/\/doi.org\/10.1002\/sim.5984.","journal-title":"Stat Med"},{"key":"18285_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109674","volume":"51","author":"SU Bae","year":"2025","unstructured":"Bae SU, Lee JL, Yang CS, et al. Survival benefit of adjuvant chemotherapy in high-risk patients with colon cancer regardless of microsatellite instability. Eur J Surg Oncol. 2025;51:109674. https:\/\/doi.org\/10.1016\/j.ejso.2025.109674.","journal-title":"Eur J Surg Oncol"},{"key":"18285_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.20.01600","volume":"39","author":"R Cohen","year":"2021","unstructured":"Cohen R, Taieb J, Fiskum J, et al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. JCO. 2021;39:642\u201351. https:\/\/doi.org\/10.1200\/JCO.20.01600.","journal-title":"JCO"},{"key":"18285_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa022289.","journal-title":"N Engl J Med"},{"key":"18285_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109\u201316. https:\/\/doi.org\/10.1200\/JCO.2008.20.6771.","journal-title":"J Clin Oncol"},{"key":"18285_CR22","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219\u201326. https:\/\/doi.org\/10.1200\/JCO.2009.27.1825.","journal-title":"J Clin Oncol"},{"key":"18285_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60\u201300 trial. J Clin Oncol. 2010;28:466\u201374. https:\/\/doi.org\/10.1200\/JCO.2009.23.3452.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"18285_CR24","doi-asserted-by":"publisher","first-page":"S630","DOI":"10.1245\/s10434-015-4807-6","volume":"22","author":"JE Kim","year":"2015","unstructured":"Kim JE, Hong YS, Kim HJ, et al. Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol. 2015;22(Suppl 3):S630\u20137. https:\/\/doi.org\/10.1245\/s10434-015-4807-6.","journal-title":"Ann Surg Oncol"},{"key":"18285_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261\u201370. https:\/\/doi.org\/10.1200\/JCO.2010.30.1366.","journal-title":"J Clin Oncol"},{"key":"18285_CR26","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1200\/JCO.2010.33.0092","volume":"29","author":"MM Bertagnolli","year":"2011","unstructured":"Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer: a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29:3153\u201362. https:\/\/doi.org\/10.1200\/JCO.2010.33.0092.","journal-title":"J Clin Oncol"},{"key":"18285_CR27","unstructured":"National Comprehensive Cancer Network. (2025). Colon Cancer (Version 4.2025). NCCN Clinical Practice Guidelines in Oncology."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18285-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:37Z","timestamp":1762352257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18285-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18285"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18285-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Emre Gorgun is a consultant for Boston Scientific, Intuitive, and DiLumen. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}